Integris Medtech IPO
Integris Medtech IPO is a Mainboard book-built issue comprising a fresh issue of up to ₹600 crore and an Offer for Sale of up to 1,08,37,266 equity shares by Evercure Holdings Pte. Ltd. The IPO is expected to open on November 27, 2026, and close on Decemb
Integris Medtech IPO Details
Integris Medtech IPO bidding is expected to open on November 27, 2026, and close on December 1, 2026. The allotment is tentatively scheduled for December 2, 2026. Refunds and demat credit are expected on December 3, while the shares are scheduled to list on BSE and NSE on December 4, 2026.
Integris Medtech IPO Timeline (Tentative)
Integris Medtech IPO is expected to open for subscription on November 27, 2026, and close on December 1, 2026. The basis of allotment is tentatively scheduled for December 2. Refund initiation and credit of shares to demat accounts are expected on December 3, followed by listing on BSE and NSE on December 4, 2026.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Fri, Nov 27, 2026 |
| IPO Close Date | Tue, Dec 1, 2026 |
| Basis of Allotment | Wed, Dec 2, 2026 |
| Initiation of Refunds | Thu, Dec 3, 2026 |
| Credit of Shares to Demat | Thu, Dec 3, 2026 |
| Listing Date | Fri, Dec 4, 2026 |
| Anchor Investor Bidding | 26 November 2026 |
Integris Medtech IPO Lot Size
The price band and minimum bid lot for Integris Medtech IPO have not yet been announced in the available offer documents. Therefore, the minimum investment and application amounts for retail and HNI categories cannot be calculated at this stage. The lot size table will be updated after the company announces the final price band and minimum bid lot.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | |||
| Retail (Max) | |||
| S-HNI (Min) | |||
| S-HNI (Max) | |||
| B-HNI (Min) |
Integris Medtech IPO Reservation
Integris Medtech IPO follows the mainboard reservation structure, with not less than 75% of the net offer reserved for Qualified Institutional Buyers, not more than 15% for Non-Institutional Investors and not more than 10% for Retail Individual Investors. The final category-wise share allocation will be based on the offer size and applicable allocation requirements.
Integris Medtech IPO Subscription
Integris Medtech IPO subscription figures will be updated once bidding begins on November 27, 2026. The issue has not yet opened, so category-wise and overall subscription figures are not available.
| Category | Subscription (times) |
|---|---|
| QIB | |
| NII | |
| RII | |
| Total |
About Integris Medtech
Integris Medtech Limited, formerly known as Integris Health Private Limited, was incorporated on April 25, 2008. It is a diversified India-based global medical products and laboratory solutions company engaged in developing, manufacturing, commercialising and selling medical devices and solutions.
The company operates across two major business divisions: cardiovascular devices and laboratory solutions. Its cardiovascular portfolio includes drug-eluting stents, drug-coated balloons, complex coronary intervention products and vascular access solutions. Its laboratory solutions business provides equipment, reagents, consumables and related services for clinical, research and industrial laboratories.
Integris Medtech operates manufacturing facilities in India, Germany and the Netherlands. Its products are sold in more than 65 international markets outside India. The company serves hospitals, laboratories, healthcare professionals and research institutions through its diversified portfolio and international distribution network.
The company manages its business across four principal markets: India, Europe, Asia excluding India and the Rest of the World, comprising the Middle East, Africa and Latin America. In India and Asia excluding India, its products cover both laboratory solutions and cardiovascular devices. Its European and Rest of the World operations are primarily focused on cardiovascular products, including its proprietary brands Chrome and Protégé and selected partner products.
Strengths
- Diversified portfolio across cardiovascular devices, clinical diagnostics and laboratory solutions.
- Manufacturing facilities in India, Germany and the Netherlands.
- Products sold in more than 65 international markets outside India.
- Broad range of medical devices, laboratory equipment, reagents and consumables.
- Presence across multiple healthcare and laboratory markets.
- Improvement in consolidated total income and profit after tax in FY2026.
- Reduction in consolidated borrowings in FY2026 compared with FY2025.
Risks to Consider
- The company operates in competitive medical device, diagnostics and laboratory solutions markets.
- Its business is subject to regulatory approvals, product quality standards and compliance requirements.
- The group depends on its subsidiaries for a significant part of its business operations.
- International operations expose the company to foreign currency and country-specific risks.
- Product development and technology changes may require continuing investment.
- Pricing pressure and competition may affect operating margins.
- The company’s future performance will depend on the operating performance of its subsidiaries and its ability to manage borrowings and working capital.
Integris Medtech Financials (₹ Cr)
Integris Medtech reported consolidated total income of ₹2,656.76 crore in FY2026 compared with ₹1,959.58 crore in FY2025. Profit after tax increased from ₹70.68 crore to ₹291.65 crore over the same period. Consolidated total assets increased to ₹4,196.89 crore, while total equity rose to ₹2,308.46 crore. Total borrowings declined to ₹832.46 crore in FY2026 from ₹1,729.46 crore in FY2025.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2025 | 1,902.47 | 70.68 | 3,641.34 | 1,321.32 |
| FY2026 | 2,578.60 | 291.65 | 4,196.89 | 2,308.46 |
KPIs & Valuation
The supplied FY2025 KPI information reports a return on equity of 5.35%, return on capital employed of 14.51% and return on net worth of 1.48%. The company’s reported EBITDA margin was 16.26%, while PAT margin was 3.72%. Its reported NAV was ₹316.09 per share and EPS was ₹6.52. The IPO price-to-earnings valuation cannot be calculated until the company announces the price band.
Objects of the Issue
Objects of the Integris Medtech IPO The company intends to utilise the net proceeds from the fresh issue primarily for repayment or prepayment of certain outstanding borrowings, including accrued interest and applicable prepayment penalties, availed by its subsidiaries, and for general corporate purposes. The company proposes to utilise the IPO proceeds for:
- Repayment or prepayment of certain outstanding borrowings, interest accrued and applicable prepayment penalties of its wholly owned subsidiaries, Translumina Therapeutics Private Limited and Transhealth Private Limited – approximately ₹93.87 crore.
- Repayment or prepayment of certain outstanding borrowings, interest accrued and applicable prepayment penalties of its step-down subsidiaries, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd. – approximately ₹415.98 crore.
- General corporate purposes – amount to be determined, subject to the prescribed limit.
- The disclosed repayment and prepayment requirement for the identified subsidiaries is approximately ₹509.85 crore. The amount allocated to general corporate purposes will be finalised after determining the net proceeds and offer-related expenses and will not exceed 25% of the gross proceeds from the fresh issue.
Promoters, Lead Managers & Registrar
Integris Medtech Limited is promoted by Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh and Punita Sharma. The updated offer structure identifies Evercure Holdings Pte. Ltd. as the promoter selling shareholder, offering up to 1,08,37,266 equity shares through the OFS. The IPO is managed by ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and IIFL Capital Services Limited, with KFin Technologies Limited as the registrar.
Promoters
Lead Managers (BRLM)
Registrar
| Name | KFin Technologies Limited |
|---|---|
| Phone | +91 40 6716 2222 / 1800 309 4001 |
| integris.ipo@kfintech.com | |
| Website | https://www.kfintech.com |
Integris Medtech IPO Review
Integris Medtech operates across cardiovascular devices, clinical diagnostics and laboratory solutions, giving it exposure to multiple segments of the healthcare and medical technology industry. Its product portfolio includes interventional cardiovascular devices, laboratory equipment, reagents and consumables. The company also has manufacturing facilities in India, Germany and the Netherlands and sells products in more than 65 international markets outside India.
The company reported a stronger consolidated financial performance in FY2026. Total income increased to ₹2,656.76 crore from ₹1,959.58 crore in FY2025, while profit after tax increased to ₹291.65 crore from ₹70.68 crore. Consolidated total borrowings declined from ₹1,729.46 crore in FY2025 to ₹832.46 crore in FY2026. These developments are important for investors evaluating the company’s earnings performance and financial position.
The proposed fresh issue of ₹600 crore is primarily intended for repayment or prepayment of borrowings of certain subsidiaries. The disclosed repayment requirement is approximately ₹509.85 crore, with the remaining proceeds intended for general corporate purposes and subject to offer-related expenses. The OFS is being undertaken by Evercure Holdings Pte. Ltd., and the proceeds from the sale will not be received by the company.
However, investors should consider the risks associated with medical device and laboratory businesses, including regulatory requirements, competition, product quality, technology changes, international operations and subsidiary-level financial performance. The final IPO valuation will also be an important factor once the price band is announced. Investors should review the final offer document and assess the company’s financial performance, business prospects and risk factors before making an investment decision.
How to Apply
Integris Medtech IPO applications can be made through the ASBA facility offered by banks or through UPI-enabled applications available on eligible stockbroker platforms. Investors should apply during the IPO bidding period after checking the final price band, lot size and application requirements. The IPO is expected to open on November 27, 2026, and close on December 1, 2026.
Through UPI
-
Log in to your stockbroker app or website.
-
Go to the IPO section.
-
Select Integris Medtech IPO.
-
Enter the number of lots you want to apply for after the lot size is announced.
-
Select the bid price. Retail investors may generally choose the cut-off option when available.
-
Enter your valid UPI ID.
-
Submit the IPO application.
-
Open your UPI app when the mandate request arrives.
-
Approve the mandate using your UPI PIN.
-
The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to the company’s Draft Red Herring Prospectus and the October 2026 addendum for information about the business, financial performance, risk factors, IPO structure and utilisation of the issue proceeds. The company’s official investor relations website provides access to its IPO and offer documents. The Red Herring Prospectus and final Prospectus should be checked when published for the latest issue terms and final offer details.
Last updated Nov 21, 2026.